Literature DB >> 23077682

2011 update in gastrointestinal cancer therapeutics.

Vaibhav Sahai1, Halla Nimeiri, Al B Benson.   

Abstract

This discussion highlights key investigational findings of existing cytotoxic and novel biological therapeutics, combination regimens, and predictive and prognostic biomarkers in the field of gastrointestinal oncology during the past year.

Entities:  

Year:  2012        PMID： 23077682      PMCID： PMC3434539     

Source DB:  PubMed          Journal:  Gastrointest Cancer Res        ISSN： 1934-7820


  15 in total

1.  Phase III trial of cetuximab with continuous or intermittent fluorouracil, leucovorin, and oxaliplatin (Nordic FLOX) versus FLOX alone in first-line treatment of metastatic colorectal cancer: the NORDIC-VII study.

Authors:  Kjell Magne Tveit; Tormod Guren; Bengt Glimelius; Per Pfeiffer; Halfdan Sorbye; Seppo Pyrhonen; Fridbjorn Sigurdsson; Elin Kure; Tone Ikdahl; Eva Skovlund; Tone Fokstuen; Flemming Hansen; Eva Hofsli; Elke Birkemeyer; Anders Johnsson; Hans Starkhammar; Mette Karen Yilmaz; Nina Keldsen; Anne Berit Erdal; Olav Dajani; Olav Dahl; Thoralf Christoffersen
Journal:  J Clin Oncol       Date:  2012-04-02       Impact factor: 44.544

2.  Association of KRAS G13D tumor mutations with outcome in patients with metastatic colorectal cancer treated with first-line chemotherapy with or without cetuximab.

Authors:  Sabine Tejpar; Ilhan Celik; Michael Schlichting; Ute Sartorius; Carsten Bokemeyer; Eric Van Cutsem
Journal:  J Clin Oncol       Date:  2012-06-25       Impact factor: 44.544

3.  Primary tumor response to preoperative chemoradiation with or without oxaliplatin in locally advanced rectal cancer: pathologic results of the STAR-01 randomized phase III trial.

Authors:  Carlo Aschele; Luca Cionini; Sara Lonardi; Carmine Pinto; Stefano Cordio; Gerardo Rosati; Salvatore Artale; Angiolo Tagliagambe; Giovanni Ambrosini; Paola Rosetti; Andrea Bonetti; Maria Emanuela Negru; Maria Chiara Tronconi; Gabriele Luppi; Giovanni Silvano; Domenico Cristiano Corsi; Anna Maria Bochicchio; Germana Chiaulon; Maurizio Gallo; Luca Boni
Journal:  J Clin Oncol       Date:  2011-05-23       Impact factor: 44.544

4.  Final results from PRIME: randomized phase III study of panitumumab with FOLFOX4 for first-line treatment of metastatic colorectal cancer.

Authors:  J Y Douillard; S Siena; J Cassidy; J Tabernero; R Burkes; M Barugel; Y Humblet; G Bodoky; D Cunningham; J Jassem; F Rivera; I Kocákova; P Ruff; M Błasińska-Morawiec; M Smakal; J L Canon; M Rother; K S Oliner; Y Tian; F Xu; R Sidhu
Journal:  Ann Oncol       Date:  2014-04-08       Impact factor: 32.976

5.  Bevacizumab beyond first progression is associated with prolonged overall survival in metastatic colorectal cancer: results from a large observational cohort study (BRiTE).

Authors:  Axel Grothey; Mary M Sugrue; David M Purdie; Wei Dong; Daniel Sargent; Eric Hedrick; Mark Kozloff
Journal:  J Clin Oncol       Date:  2008-10-14       Impact factor: 44.544

6.  Revised TN categorization for colon cancer based on national survival outcomes data.

Authors:  Leonard L Gunderson; John Milburn Jessup; Daniel J Sargent; Frederick L Greene; Andrew K Stewart
Journal:  J Clin Oncol       Date:  2009-11-30       Impact factor: 44.544

7.  Cetuximab for the treatment of colorectal cancer.

Authors:  Derek J Jonker; Chris J O'Callaghan; Christos S Karapetis; John R Zalcberg; Dongsheng Tu; Heather-Jane Au; Scott R Berry; Marianne Krahn; Timothy Price; R John Simes; Niall C Tebbutt; Guy van Hazel; Rafal Wierzbicki; Christiane Langer; Malcolm J Moore
Journal:  N Engl J Med       Date:  2007-11-15       Impact factor: 91.245

8.  Clinical outcome of the ACCORD 12/0405 PRODIGE 2 randomized trial in rectal cancer.

Authors:  Jean-Pierre Gérard; David Azria; Sophie Gourgou-Bourgade; Isabelle Martel-Lafay; Christophe Hennequin; Pierre-Luc Etienne; Véronique Vendrely; Eric François; Guy de La Roche; Olivier Bouché; Xavier Mirabel; Bernard Denis; Laurent Mineur; Jean-François Berdah; Marc-André Mahé; Yves Bécouarn; Olivier Dupuis; Gérard Lledo; Jean-François Seitz; Laurent Bedenne; Béata Juzyna; Thierry Conroy
Journal:  J Clin Oncol       Date:  2012-10-29       Impact factor: 44.544

9.  Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer.

Authors:  Carsten Bokemeyer; Igor Bondarenko; Anatoly Makhson; Joerg T Hartmann; Jorge Aparicio; Filippo de Braud; Serban Donea; Heinz Ludwig; Gunter Schuch; Christopher Stroh; Anja H Loos; Angela Zubel; Piotr Koralewski
Journal:  J Clin Oncol       Date:  2008-12-29       Impact factor: 44.544

10.  Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial.

Authors:  Timothy S Maughan; Richard A Adams; Christopher G Smith; Angela M Meade; Matthew T Seymour; Richard H Wilson; Shelley Idziaszczyk; Rebecca Harris; David Fisher; Sarah L Kenny; Edward Kay; Jenna K Mitchell; Ayman Madi; Bharat Jasani; Michelle D James; John Bridgewater; M John Kennedy; Bart Claes; Diether Lambrechts; Richard Kaplan; Jeremy P Cheadle
Journal:  Lancet       Date:  2011-06-05       Impact factor: 79.321
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.